Home > Insider Trading > Filing (0001225208-17-010827)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1183765	Threshold Pharmaceuticals Inc	THLD	Pharmaceutical Preparations (2834)	943409596

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1250409	W Jeffrey Bird	755 Page Mill Road, Suite A-200 Palo Alto CA 94304-1005		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2017-05-31	630,770	$0.00	3,467,496	No	4	J	Indirect	By Ltd Partnership (SHV)
Common Stock	Acquisiton	2017-06-01	473,077	$0.57	3,940,573	No	4	P	Indirect	By Ltd Partnership (SHV)
Common Stock	Acquisiton	2017-06-01	37,626	$0.57	377,782	No	4	P	Indirect	By Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	J	Indirect	By Ltd Partnership (SHV)
No	4	P	Indirect	By Ltd Partnership (SHV)
No	4	P	Indirect	By Trust

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	919	Direct

Footnotes

On May 31, 2017, a limited partner (the "Limited Partner") of Sutter Hill Ventures, a California Limited Partnership ("SHV") liquidated its interest in SHV in return for its ratable share of the holdings of SHV, resulting in SHV's disposition to the Limited Partner of 630,770 shares (the "Distributed Common Shares") of the Issuer's common stock (the "Liquidation").
Shares held by SHV. The reporting person is a managing director and member of the management committee of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
In connection with the Liquidation, SHV entered into an agreement with the Limited Partner to repurchase 473,077 Distributed Common Shares from the Limited Partner at a purchase price equal to the average of the mean between the closing bid and ask prices over the ninety (90)-day period ended March 31, 2017.
In connection with the Liquidation, the reporting person entered into an agreement with the Limited Partner to repurchase 37,626 Distributed Common Shares from the Limited Partner at a purchase price equal to the average of the mean between the closing bid and ask prices over the ninety (90)-day period ended March 31, 2017.
Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.